<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04093349</url>
  </required_header>
  <id_info>
    <org_study_id>SPK-3006-101</org_study_id>
    <secondary_id>2019-001283-30</secondary_id>
    <nct_id>NCT04093349</nct_id>
  </id_info>
  <brief_title>A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)</brief_title>
  <official_title>Phase 1/2, Dose-escalation Study to Evaluate the Safety, Tolerability and Efficacy of a Single Intravenous Infusion of SPK-3006 in Adults With Late-onset Pompe Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spark Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spark Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and efficacy of a single
      intravenous infusion of SPK-3006 in adults with clinically moderate, late-onset Pompe disease
      receiving enzyme replacement therapy (ERT). Participants will be treated in sequential,
      dose-level cohorts.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Due to the COVID-19 pandemic, enrollment has been suspended until further notice
  </why_stopped>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse and serious adverse events (AEs/SAEs), including clinically significant abnormal laboratory values.</measure>
    <time_frame>52 weeks</time_frame>
    <description>Adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of immune response against AAV capsid</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of immune response against GAA transgene</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Pompe Disease</condition>
  <condition>Pompe Disease (Late-onset)</condition>
  <condition>Glycogen Storage Disease Type 2</condition>
  <condition>Glycogen Storage Disease Type II</condition>
  <condition>LOPD</condition>
  <condition>Lysosomal Storage Diseases</condition>
  <condition>Acid Maltase Deficiency</condition>
  <arm_group>
    <arm_group_label>SPK-3006</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants who meet the eligibility criteria will receive a single intravenous (i.v.) administration of SPK-3006.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>SPK-3006</intervention_name>
    <description>adeno-associated viral (AAV) vector</description>
    <arm_group_label>SPK-3006</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide written informed consent;

          -  Males and Females â‰¥18 years of age with late-onset Pompe disease;

          -  Received ERT for at least the previous 24 months

          -  Have clinically moderate, late-onset Pompe disease characteristics;

          -  Agree to use reliable contraception.

        Exclusion Criteria:

          -  Active hepatitis B and/or C;

          -  Significant underlying liver disease;

          -  Human immunodeficiency virus (HIV) infection;

          -  Prior hypersensitivity to rhGAA;

          -  Pre-existing anti-AAV neutralizing antibody titers;

          -  High titer antibody responses to rhGAA;

          -  Requires any invasive ventilation or requires noninvasive ventilation while awake and
             upright;

          -  Received any prior vector or gene transfer agent;

          -  Active malignancy (except non-melanoma skin cancer);

          -  History of liver cancer;

          -  Pregnant or nursing women;

          -  Any evidence of active infection at the time of SPK-3006 infusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tahseen Mozaffar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California Irvine Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Irvine Health</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 16, 2019</study_first_submitted>
  <study_first_submitted_qc>September 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2019</study_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycogen Storage Disease Type II</mesh_term>
    <mesh_term>Glycogen Storage Disease</mesh_term>
    <mesh_term>Lysosomal Storage Diseases</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

